ADHD Medication Use Doubled in Five Years. Data Points to a Missing Conversation.

The Numbers Behind the Surge

Israel’s Ministry of Health tracked ADHD medication consumption across the country from 2020 through 2025. Total consumption nearly doubled in five years. The composition shifted sharply: methylphenidate-class drugs, historically the first-line choice, now hold only a third of the market. Amphetamine-family drugs, which carry a higher misuse profile, filled the gap and now represent the majority of all ADHD prescriptions in the country.

Israel is not the outlier it might appear. A 2025 narrative review in the Journal of Clinical Medicine mapped ADHD medication consumption across countries and found steady climbs in most nations. The United States, representing less than 5% of the global population, accounts for 83% of global ADHD medication volume. US stimulant prescriptions surged 250% between 2006 and 2016, a period when ADHD prevalence itself changed only minimally. A 2025 analysis in Frontiers in Psychiatry drew an explicit comparison to the opioid crisis trajectory: amphetamine production in 2006 was roughly 7.9 million grams; by 2021 it had tripled.

A national US survey covering 2019 to 2022 found that approximately one in four adults using prescription stimulants reported misuse, and nearly 9% met criteria for prescription stimulant use disorder, with higher misuse rates among those taking amphetamine-based drugs compared to methylphenidate.

A Prescription Manages the Day. It Does Not Train the Brain That Runs It.

Here is what the coverage rarely says plainly: a stimulant medication manages attention during the hours it is active. It does not train the underlying systems that produce attention. When a child takes it and functions better at school, the working memory, self-regulation, and organizational systems that ADHD disrupts remain untrained. The medication is doing the regulating. That is useful for getting through a school day. It is not sufficient for building a brain that regulates itself when the medication is not on board.

Special education’s own research is clear-eyed on this pattern. It describes a “differential boost” — the right support, at the right moment, lifts a struggling learner more than it lifts anyone else. That is a scaffold doing its job. But the same research documents the failure mode: when a support removes the pressure to build the underlying skill, dependence sets in. The question is not “medication: yes or no.” It is “is this treatment also building something that lasts?”

The skills-based evidence is real and growing. A 2017 meta-analysis of organizational skills training for adolescents with ADHD found effect sizes of 0.54 to 0.83 — meaningful, durable gains in task management, time management, and planning. Aerobic exercise interventions consistently show cognitive benefits for children who struggle with attention. Behavioral therapy, neuroplasticity-based training, and cognitive approaches are better studied than most parents know. These are not fringe alternatives. They are evidence-backed options a system optimized for efficiency rarely leads with, because writing a prescription is faster.

What to Ask Before Accepting the Next Prescription as the Full Answer

None of this means medication is wrong for your child. For many children with genuine ADHD, the right medication at the right dose changes what is possible in ways that cannot be reached otherwise. The data does not argue against it. It argues for holding the treatment plan to a higher standard.

Ask the prescriber: what is the plan for building the underlying skills alongside this medication? Is there a behavioral or skills-based component? Are we tracking whether the skills themselves are developing, or only whether the school day is running more smoothly?

Ask yourself what your child understands about their own brain. A child who sees their attention system as something being trained — not fixed, not broken — brings a different quality of effort to that work. Brain-imaging studies from Yale and Stanford show that children who struggle with reading and attention develop the same cognitive pathways as typical learners after intensive, appropriate practice. The brain you are worried about today is not the brain your child will have after a year of the right kind of effort. That is not a motivational claim. It is what the neuroplasticity research actually shows.

The 98% surge in Israel, like the 250% US surge a decade ago, reflects a system that found medication efficient. Efficiency and effectiveness are not the same thing.